Drugs /

anti-irf4 antisense oligonucleotide ion251

Back to Drugs List

Overview

NCI Definition [1]:
An antisense oligonucleotide (ASO) targeting the interferon regulatory factor 4 (IRF4) mRNA, with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-IRF4 ASO ION251 hybridizes with IRF4 mRNA, which blocks translation of the IRF4 protein. Reduction of IRF4 levels prevents the expression of IRF4-controlled tumor promoter genes, and may enhance tumor cell apoptosis and prevent T-cell exhaustion. IRF4, a transcription factor expressed in lymphocytes and essential for plasma cell differentiation, is involved in immune cell development and plays a key role in T-cell functions. It is overexpressed in certain tumor cell types and is a key regulator of multiple genes controlling tumor cell survival.

Clinical Trials

View Clinical Trials for anti-irf4 antisense oligonucleotide ion251

Anti-irf4 antisense oligonucleotide ion251 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating anti-irf4 antisense oligonucleotide ion251, 1 is phase 1 (1 open).

Multiple myeloma is the most common disease being investigated in anti-irf4 antisense oligonucleotide ion251 clinical trials [2].

Drug Details

Synonyms [2]:
anti-irf4 aso ion251, anti-irf4 aso ionis-irf4-2.5rx, ion 251, ion251, ion-251, onis-irf4-2.5rx
Drug Target(s) [2]:
IRF4
NCIT ID [1]:
C173725

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.